Moreover, the combination of anti-PD-1 and anti-CTLA-4 with whole tumor cell vaccination exhibited impressive results and was able to counter the adaptive immune resistance to elicit strong tumor efficacy in a mouse NBL model [126]. This evidence concerns the gene PDCD1 and neoplasm.